A Phase 4 interventional study of Early initiation of continuous renal replacement therapy and Standard initiation of continuous renal replacement therapy in Cardiogenic Shock and Acute Kidney Injury, sponsored by Samsung Medical Center. Recruiting at 2 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-01-05.
Sponsored by Samsung Medical Center · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Shock, Cardiogenic with a site in Korea, Republic of — 8 open to participants now, 8 under way, none of them phase 3. Shock, Cardiogenic · Korea, Republic of.
Among the 13 studies in Shock, Cardiogenic with a site in Korea, Republic of, this one is the 4th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is one of 2 in phase 4, and was the 10th registered.
297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.
Browse Shock, Cardiogenic studies →8 of the 13 studies in Shock, Cardiogenic with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Min-Seok Kim · Sites in Korea, Republic of
Ages 19+
Min-Seok Kim · Sites in Korea, Republic of
Ages 19+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 408 is above the median of 80 across 133 interventional studies indexed under Shock, Cardiogenic.
Median enrollment 280 across the 10 interventional studies, 1,000 across the 3 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 6 most frequent:
Samsung Medical Center is the lead sponsor of 1,013 studies on the registry; 153 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
Samsung Medical Center has 6 studies filed under Shock, Cardiogenic — fewer than ten, so there is no comparison to draw.
2 of the studies in Shock, Cardiogenic with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05698628Min-Seok KimDistal Perfusion Timing, Early or Conservative, to Prevent Limb Ischemia During Peripheral VA-ECMO | 2027-02-28 |
| NCT06078436Min-Seok KimPulmonary Artery Catheterization and Carvedilol Early Initiation in Cardiogenic SHOCK Due to HFrEF | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Shock, Cardiogenic with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was designed to compare the safety and efficacy of early continuous renal replacement therapy with standard continuous renal replacement therapy in the presence of acute kidney injury (stage 2 or greater acute kidney injury according to the KDIGO [The Kidney Disease: Improving Global Outcomes] classification) in patients with advanced cardiogenic shock on extracorporeal membrane oxygenation.
Patients with cardiogenic shock who are placed on extracorporeal membrane oxygenation devices often have increased afterload due to the retrograde arterial flow of the device, resulting in increased left ventricular filling pressures, and optimal full-load management in these patients may be important to improve prognosis. Previous observational studies have reported that the use of renal replacement therapy for full-load management in patients with cardiogenic shock on extracorporeal membrane oxygenation is effective and improves patient survival in cases of severe renal dysfunction when fluid volume reduction is maintained. However, to date, there have been no randomized controlled studies to identify the optimal timing of renal replacement therapy in patients with cardiogenic shock on extracorporeal membrane oxygenation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
C. Sign of impaired organ perfusion with at least one of the following:
serum lactate > 2.0 mmol/l.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the accelerated-strategy group, RRT is initiated as soon as possible and within 6 hours after patients have met full eligibility criteria.
Device: Early initiation of continuous renal replacement therapy
Clinicians were discouraged from initiating RRT until the development of one or more of the following criteria. * Serum potassium \> 6.5 mmol/L * Serum potassium\> 6.0 mmol/L persisting despite medical treatment * Metabolic acidosis (pH \< 7.15 and PaCO2 \< 35 mmHg or serum bicarbonate \< 12 mmol/L) * Blood urea nitrogen level ≥100 mg/dL * Oliguria (≤0.3 ml/kg/hour) or anuria for 48h or more * Diuretics refractory fluid overload or pulmonary edema
Device: Standard initiation of continuous renal replacement therapy
Patients will be randomized to either the standard initiation of the CRRT group or the accelerated initiation of the CRRT group with a 1:1 ratio.
Patients will be randomized to either the standard initiation of the CRRT group or the accelerated initiation of the CRRT group with a 1:1 ratio.
all-cause mortality or RRT dependence
Time frame: 90 days after patient enrollment
In-hospital mortality
Time frame: Up to 30 days
In-hospital cardiac mortality
Time frame: Up to 30 days
VA-ECMO weaning success
Time frame: Up to 30 days
Time to VA-ECMO weaning
Time frame: Up to 30 days
Critical limb ischemia
Time frame: Up to 30 days
Access site major bleeding
Bleeding Academic Research Consortium \[BARC\] type 3-5
Time frame: Up to 30 days
CPC 3-5
Cerebral Performance Category
Time frame: Up to 30 days
Length of intensive-care unit stay
ICU Stay
Time frame: Up to 30 days
Length of hospital stay
Hospital stay
Time frame: Up to 30 days
Duration of mechanical ventilation
Mechanical Ventilation Maintenance
Time frame: Up to 30 days
Duration of RRT
Renal Replacement Therapy
Time frame: Up to 30 days
all-cause mortality
Time frame: 90 days & 12 months after patient enrollment
cardiac mortality
Time frame: 90 days & 12 months after patient enrollment
Requirement of cardiac replacement therapy
Left ventricular assisted device implantation or heart transplantation
Time frame: 90 days & 12 months after patient enrollment
re-hospitalization due to heart failure
Time frame: 90 days & 12 months after patient enrollment
re-hospitalization due to any cause
Time frame: 90 days & 12 months after patient enrollment
cerebrovascular accident
ischemic or hemorrhagic
Time frame: 90 days & 12 months after patient enrollment
RRT dependence
Time frame: 90 days & 12 months after patient enrollment
Serum creatinine and eGFR
Time frame: 90 days & 12 months after patient enrollment
major bleeding (BARC type 3, or 5)
Time frame: 90 days & 12 months after patient enrollment
clinically meaningful bleeding (BARC type 2, 3, or 5)
Time frame: 90 days & 12 months after patient enrollment
Patients in the standard strategy group who received emergency RRT before 48 hours, according to criterion
Time frame: Up to 48 hours
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2028, 48 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.